SCA Prep

Mental Health

Depression, anxiety, psychosis, eating disorders and mental health crisis management.

Last reviewed

Use this quick reference guide to study and ensure you have mastered these common cases from the curriculum. You can generate specific cases on our SCA cases page or even practice them with our specialised and UK guidelines trained AI Actors.

1Depression in Adults

Depression means persistent low mood and/or loss of interest or pleasure (anhedonia), most of the day, nearly every day, for at least 2 weeks, with other symptoms such as poor sleep, fatigue, poor concentration, guilt or thoughts of death.

Visual explanation

Behavioural activation: start with a manageable activity

Two examples rather than a recovery sequence: a woman prepares a simple meal at home, and the same woman takes a short walk with a friend.

An everyday task

Choose a small, specific action that feels achievable, such as preparing something to eat.

Something personally meaningful

Plan an activity the person values, such as a short walk with someone they trust.

Remember: Behavioural activation explores the link between activity and mood. Agree realistic steps together, review the effect on mood and daily functioning, and build gradually.

Illustrative activity examples. Sources: NICE NG222: behavioural activation

Assessment

Ask the two depression questions (feeling down or hopeless, and little interest or pleasure in doing things) to identify possible depression. A validated measure such as the PHQ-9 helps judge severity and track response, but do not rely on the score alone. NICE groups a new episode as less severe (PHQ-9 under 16) or more severe (16 or more). Always ask about suicidal ideation.

Less Severe Depression

If the person does not want treatment or is already improving, offer active monitoring and reassess within 2 to 4 weeks. Otherwise discuss the NICE options, starting with guided self-help. Others include group CBT, group behavioural activation, individual CBT or behavioural activation, group exercise, group mindfulness, interpersonal therapy and counselling. Do not routinely offer an antidepressant first line; offer one only if that is the person's informed preference.

More Severe Depression

  • First-line: Discuss all the NICE options. Combined individual CBT and an antidepressant is listed first, but CBT, behavioural activation, an antidepressant alone and other therapies can all be first line. If an antidepressant is chosen, an SSRI is usually first choice.
  • Citalopram: Maximum 40 mg a day, or 20 mg if over 65 or with liver impairment. Do not combine it with other drugs that prolong the QT interval.
  • Review: Usually within 2 weeks of starting. If the person is 18 to 25, or there is particular concern about suicide, review 1 week after starting or after any dose increase. Then review again no later than 4 weeks after starting.
  • Duration: Continue for at least 6 months after remission to prevent relapse.
  • Switching: If there is no response after 4 weeks at a therapeutic dose, check adherence and anything else that could explain it. Options then include increasing the dose, switching to another SSRI or to another class such as an SNRI, or adding or switching to a psychological therapy.
  • Stopping: Reduce the dose in steps over weeks or longer, because withdrawal symptoms can be severe.

2Generalised Anxiety Disorder (GAD) and Panic

GAD involves excessive worry about multiple events/activities for >6 months. Panic disorder involves recurrent unexpected panic attacks.

Diagnosis

Consider the GAD-2 to identify possible GAD. The GAD-7 can help rate severity and track progress, but the diagnosis is clinical. Rule out organic causes (e.g., hyperthyroidism).

Management

  • Step 1: Psychoeducation, active monitoring.
  • Step 2: If symptoms have not improved, offer low-intensity psychological interventions: individual non-facilitated self-help, individual guided self-help or psychoeducational groups.
  • Step 3: For marked functional impairment, or no improvement after step 2: CBT or applied relaxation, or drug treatment, depending on the person's preference.
  • Step 4: Specialist care for complex, treatment-resistant GAD with very marked functional impairment, such as self-neglect or a high risk of self-harm.

Pharmacology

If drug treatment is chosen, offer sertraline first. If it does not work, offer another SSRI or an SNRI. Consider pregabalin only if the person cannot tolerate SSRIs or SNRIs; it is a controlled drug with a risk of misuse and dependence. Do not offer a benzodiazepine except short term in a crisis, and do not offer an antipsychotic in primary care. If someone under 30 starts an SSRI or SNRI, warn them about a possible increase in suicidal thoughts, see them within 1 week, then weekly for the first month.

Panic Disorder

Offer self-help or CBT. If medication is needed, offer an SSRI licensed for panic disorder. If there is no improvement after 12 weeks, consider imipramine or clomipramine. Do not prescribe benzodiazepines, sedating antihistamines or antipsychotics for panic disorder.

3Self-Harm and Suicide Risk Assessment

No risk assessment tool can predict suicide. Clinical judgement is key. Do not label people as low, medium or high risk; focus on their needs and how to keep them safe.

Assessment

  • Intent: Was there an intention to die? Did they think it would be fatal?
  • Planning: Was it impulsive or planned? Did they leave a note? Did they take precautions against discovery?
  • Current State: Do they regret surviving? Do they still feel suicidal?
  • Protective Factors: Family, children, hope for future.

If There Is Immediate Danger

Refer the same day to the crisis resolution and home treatment team. Send them to A&E if they have an injury or an overdose that needs treatment.

If There Is No Immediate Danger

Agree a written safety plan with the person. Involve family or friends if they agree. Treat any mental illness and consider referral to mental health services. If there are ongoing safety concerns after self-harm, arrange initial aftercare within 48 hours of the psychosocial assessment.

4Bipolar Disorder

Characterised by episodes of mania/hypomania and depression.

Recognition

When someone presents with depression, ask about past periods of overactivity or disinhibited behaviour. If these lasted 4 days or more, consider referral for specialist assessment.

Referral

Do not start antidepressants alone in suspected bipolar depression (risk of precipitating mania). Refer to psychiatry.

Management

  • Lithium: First-line long-term treatment, started by specialists or under shared care. Check levels 1 week after starting and after each dose change, weekly until stable, then every 3 months for the first year. After that, 6-monthly levels are allowed in stable people, but keep checking every 3 months in older people, people on interacting drugs, people with kidney, thyroid or calcium problems, poor control or poor adherence, or a last level of 0.8 mmol/L or more. Check weight or BMI, U&Es with eGFR, calcium and thyroid function every 6 months. The usual target is 0.6 to 0.8 mmol/L. Signs of toxicity: Coarse tremor, vomiting, confusion, ataxia.
  • Valproate: Must not be started in anyone under 55, male or female, unless two specialists independently agree and record that nothing else works or is tolerated, or that the reproductive risks do not apply. In women and girls who could become pregnant, use it only if other options are unsuitable and the Pregnancy Prevention Programme is in place. Advise men to use effective contraception during treatment and for 3 months after stopping. Do not start valproate for bipolar disorder in primary care.

5Psychosis and Schizophrenia

Psychosis involves loss of contact with reality (hallucinations, delusions).

First Episode Psychosis

Refer without delay to the Early Intervention in Psychosis (EIP) service. The national standard is that at least 60% of people start NICE-recommended treatment within 2 weeks of referral. Do not start an antipsychotic in primary care unless a consultant psychiatrist advises it.

Physical Health

People with severe mental illness (SMI) have reduced life expectancy (15-20 years less).

Annual Health Check

Offer everyone on the SMI register a physical health check at least once a year. The core six checks are:

  • • BMI and blood pressure.
  • • HbA1c or glucose, and lipids.
  • • Smoking status and alcohol intake.
  • • A fuller check adds a cardiovascular risk score such as QRISK3.
  • • An ECG is not a routine annual test. Arrange one before starting an antipsychotic if the product information requires it, if there is cardiovascular disease or risk (such as hypertension), or if monitoring shows a need.

6Perinatal Mental Health

Mental health problems during pregnancy and the first year after birth.

Red Flags: Postpartum Psychosis

Psychiatric emergency. Symptoms include rapid onset confusion, hallucinations, and delusions (often about the baby). Refer to secondary mental health services, preferably the perinatal team, for assessment within 4 hours. If she needs admission, this should normally be to a mother and baby unit.

Depression/Anxiety

Balance risk of medication vs. risk of untreated illness.

  • • In breastfeeding, sertraline and paroxetine are the preferred SSRIs because little passes into breast milk.
  • • In pregnancy, paroxetine is not usually a first choice: first-trimester use has been linked to a small increase in heart defects, and it causes more neonatal withdrawal.
  • • Valproate: Do not offer it for a mental health problem in women or girls who could become pregnant, unless other options are ineffective or not tolerated and the Pregnancy Prevention Programme is in place. If she becomes pregnant, advise her to stop it.
  • • Carbamazepine and lithium: Do not offer carbamazepine to women planning a pregnancy, pregnant or considering breastfeeding. Only offer lithium in pregnancy if antipsychotics have not worked.

Referral

Refer to secondary mental health services, preferably the specialist perinatal team, any woman who has or may have a severe mental illness, or who has had one in the past, even if she is well now. Moderate depression is usually treated with high-intensity psychological therapy, with or without an antidepressant, following local referral criteria.

7Eating Disorders

Includes Anorexia Nervosa, Bulimia Nervosa, and Binge Eating Disorder.

Screening

The SCOFF questionnaire (Sick, Control, One stone, Fat, Food) can help, but do not use a screening tool on its own to decide whether someone has an eating disorder.

Physical Assessment

Assess medical risk using the MEED guidance. Check:

  • • BMI (or % median BMI in under-18s) and rate of weight loss. BMI can be normal in bulimia.
  • • Heart rate, lying and standing blood pressure, and temperature.
  • • Muscle strength (sit-up-squat-stand test).
  • • ECG (QTc).
  • • Bloods (FBC, U&Es, LFTs, Calcium, Phosphate, Magnesium, Glucose).

Referral

If you suspect an eating disorder, refer straight away to the community eating disorder service. Do not use BMI or illness duration alone to decide. If there are red flags, such as BMI under 13, a pulse under 40, a big postural drop in blood pressure, a temperature under 35.5°C or a failed sit-up-squat-stand test, arrange urgent medical assessment, often in A&E.

8Post-Traumatic Stress Disorder (PTSD)

Symptoms following a traumatic event, persisting for >1 month.

Symptoms

Re-experiencing (flashbacks/nightmares), Avoidance, Hyperarousal (vigilance/startle response), Emotional numbing.

Management

  • First Month: Within 1 month of a trauma, consider active monitoring for subthreshold symptoms, with follow-up within 1 month. Offer trauma-focused CBT for acute stress disorder or clinically important PTSD symptoms.
  • Psychological: Offer trauma-focused CBT to adults who present more than 1 month after a trauma. Offer EMDR (Eye Movement Desensitisation and Reprocessing) to adults with PTSD more than 3 months after a non-combat trauma, and consider it at 1 to 3 months if they prefer it.
  • Drug Treatment: Consider venlafaxine or an SSRI such as sertraline if the person prefers drug treatment, and review it regularly. Do not use any drug, including benzodiazepines, to prevent PTSD.

9Obsessive Compulsive Disorder (OCD)

Characterised by obsessions (intrusive thoughts) and compulsions (ritualistic behaviours to relieve anxiety).

Visual explanation

OCD: why short-term relief can keep the cycle going

  1. 1

    Intrusive thought

    An unwanted thought, image or urge repeatedly enters the mind.

  2. 2

    Anxiety or distress

    The intrusion feels upsetting or threatening.

  3. 3

    Compulsion

    A repeated action or mental ritual is used to try to reduce the distress.

  4. 4

    Temporary relief

    Distress eases briefly, but the obsession and anxiety return.

The thought and distress return, and the urge to repeat the ritual can grow.

Remember: Compulsions can be mental acts as well as visible behaviours. CBT with exposure and response prevention helps a person face the fear without performing the compulsion.

Simplified teaching diagram. Sources: NHS: OCD symptoms · NHS: OCD treatment

Diagnosis

Do the obsessions/compulsions take up >1 hour a day or cause significant distress/impairment?

Management

  • Mild: Low-intensity psychological treatment (ERP - Exposure and Response Prevention).
  • Moderate: A choice of an SSRI or more intensive CBT (including ERP).
  • Severe: An SSRI together with CBT (including ERP).

Medication

SSRIs (Fluoxetine, Sertraline) often require higher doses than for depression and take longer (up to 12 weeks) to show effect.

10Insomnia and Sleep Disorders

Difficulty initiating or maintaining sleep.

Assessment

Check sleep hygiene (caffeine, screens, routine). Screen for depression/anxiety or physical causes (pain, nocturia, sleep apnoea).

Management

  • First-line: For insomnia lasting 3 months or more, CBT for Insomnia (CBT-I), face to face or digital (such as Sleepio). Sleep hygiene on its own is not an effective treatment for chronic insomnia; it helps in short-term insomnia, or as part of CBT-I.
  • Pharmacology: If a hypnotic is needed for severe short-term insomnia, use the lowest dose for the shortest time: no more than 2 weeks, and ideally less than 1 week. The licensed maximum for zopiclone is 4 weeks, including the taper. In chronic insomnia, use only a short course as a temporary add-on to CBT-I.
  • Other options: Daridorexant if CBT-I has not worked or is not available (NICE TA922). Prolonged-release melatonin for people aged 55 and over.

Risks

Dependence and withdrawal, falls and confusion in older people, and next-day drowsiness that impairs driving: patients should not drive for 12 hours after taking zopiclone. Combining it with alcohol or opioids risks dangerous sedation, and complex sleep behaviours such as sleep driving can occur. Zopiclone is contraindicated in severe sleep apnoea and respiratory failure.